体检胃蛋白酶原、胃泌素17异常人群血清CA19-9、CA72-4与CEA水平表达分析  

Expression Analysis of Serum CA19-9,CA72-4 and CEA Levels in Patients With Abnormal Pepsinogen and Gastrin 17 Levels During Physical Examination

作　　者：张淑莲 王艺娜 王思敏 方超兰 ZHANG Shulian;WANG Yina;WANG Simin;FANG Chaolan(Department of Clinical Laboratory,the 910th Hospital of the Joint Logistics Support Force of the People's Liberation Army of China,Quanzhou Fujian 362000,China)

机构地区：[1]中国人民解放军联勤保障部队第九一〇医院检验科,福建泉州362000

出　　处：《中国卫生标准管理》2024年第16期89-92,共4页China Health Standard Management

摘　　要：目的研究体检人群血清胃蛋白酶原Ⅰ(pepsinogenⅠ,PGⅠ)、胃蛋白酶原Ⅱ(pepsinogenⅡ,PGⅡ)、胃泌素17(gastrin 17,G-17)和胃蛋白酶原Ⅰ与胃蛋白酶原Ⅱ比值(pepsinogenⅠ/pepsinogenⅡ,PGR)异常情况下血清中糖类抗原19-9(carbohydrate antigen 19-9,CA19-9)、糖类抗原72-4(carbohydrate antigen 72-4,CA72-4)、癌胚抗原(carcinoembryonic antigen,CEA)水平表达分析。方法选取2021年1月—2023年12月在中国人民解放军联勤保障部队第九一〇医院健康管理中心体检的4354例体检者。依据G-17、PGⅠ、PGⅡ、PGR是否异常分为胃癌低风险G-17(-)和PG(-)组、有胃癌风险G-17(+)或PG(+)组、胃癌高风险G-17(+)和PG(+)组。采用酶联免疫吸附试验(enzyme-linked immunosorbent assay,ELISA)法检测外周血中PGⅠ、PGⅡ和G-17水平及用化学发光法检测外周血CA19-9、CA72-4、CEA水平。结果胃癌低风险G-17(-)和PG(-)组血清CA19-9水平为9.84(6.72,14.72)IU/mL,有胃癌风险G-17(+)或PG(+)组血清CA19-9水平为9.39(6.26,14.27)IU/mL,胃癌高风险G-17(+)和PG(+)组血清CA19-9水平为11.03(6.02,17.90)IU/mL,差异有统计学意义(P<0.05)。胃癌高风险G-17(+)和PG(+)组血清CA72-4浓度为1.16(0.44,2.13)IU/mL,胃癌低风险G-17(-)和PG(-)组CA72-4浓度为1.49(0.62,3.32)I U/m L,有胃癌风险G-17(+)或PG(+)组CA 72-4浓度为1.47(0.64,3.18)I U/m L,差异有统计学意义(P<0.05)。结论G-17(+)和(或)PG(+)异常情况下,联合检测CA19-9、CA72-4血清水平且综合考虑体检者临床症状能很好地反映体检者胃部健康状况,及时发现胃部问题,积极行胃镜精查及治疗,必要时行外科手术治疗。Objective To study the expression levels analysis of carbohydrate antigen 19-9(CA19-9),carbohydrate antigen 72-4(CA72-4),and carcinoembryonic antigen(CEA)in the serum of individuals undergoing physical examination under abnormal serum levels of pepsinogenⅠ(PGⅠ),pepsinogenⅡ(PGⅡ),gastrin 17(G-17)and pepsinogenⅠ/pepsinogenⅡ(PGR).Methods A total of 4354 examinees who underwent physical examinations at the health management center,the 910th Hospital of the Joint Logistics Support Force of the People's Liberation Army of China from January 2021 to December 2023 were selected.They were divided into low-risk G-17(-)and PG(-)groups,high-risk G-17(+)or PG(+)groups,and high-risk G-17(+)and PG(+)groups for gastric cancer according to whether G-17,PGⅠ,PGⅡand PGR were abnormal.The levels of PGⅠ,PGⅡand G-17 in peripheral blood were detected by enzyme-linked immunosorbent assay(ELISA),and the levels of CA19-9,CA72-4 and CEA in peripheral blood were detected by chemiluminescence assay.Results The serum CA19-9 concentration in the low-risk G-17(-)and PG(-)groups for gastric cancer was 9.84(6.72,14.72)IU/mL,while the CA19-9 concentration in the high-risk G-17(+)or PG(+)groups for gastric cancer was 9.39(6.26,14.27)IU/mL,and the CA19-9 concentration in the high-risk G-17(+)and PG(+)groups for gastric cancer was 11.03(6.02,17.90)IU/mL,the difference was statistically significant(P<0.05).The serum CA72-4 levels in the high-risk G-17(+)and PG(+)groups for gastric cancer was 1.16(0.44,2.13)IU/mL,while serum CA72-4 levels in the lowrisk G-17(-)and PG(-)groups for gastric cancer was 1.49(0.62,3.32)IU/mL,and serum CA72-4 levels in the high-risk G-17(+)or PG(+)groups for gastric cancer was 1.47(0.64,3.18)IU/mL,the difference was statistically significant(P<0.05).Conclusion When G-17(+)and(or)PG(+)were abnormal,the combined detection of serum levels of CA19-9 and CA72-4 and the comprehensive consideration of clinical symptoms could well reflect the stomach health status of the subjects,timely detection of stomach problems

关 键 词：胃蛋白酶原Ⅰ 胃蛋白酶原Ⅱ 胃泌素17 糖类抗原19-9 糖类抗原72-4 癌胚抗原 

分 类 号：R573[医药卫生—消化系统]